Results published in the Journal Immunity share discovery of a new mechanism by which Chi3L1 regulates breast cancer development and progression PROVIDENCE, Rhode Island, Dec. 05, 2023 (GLOBE NEWSWIRE ...
Ocean’s breakthrough approach to malaria prevention and treatment targets the blood-stage portion of the malaria lifecycle – the stage responsible for all clinical disease and death – and therefore ...
Providence, RI, April 06, 2023 (GLOBE NEWSWIRE) -- Ocean Biomedical, Inc. (NASDAQ: OCEA) announced today a strong commitment to targeting its pulmonary fibrosis treatment candidate, “OCF-203,” as a ...
Ocean Biomedical announced that Dr. Jonathan Kurtis and his team have secured significant funding from the NIH to advance their malaria vaccine research, which focuses on a unique protein found on ...
Ocean Biomedical has announced promising research findings on its cancer immunotherapy candidates, which can enhance the effectiveness of tyrosine kinase inhibitors (TKIs) like osimertinib for ...
Ocean Biomedical’s Inclusion in the Russell 2000 ® Index and Russell 3000 ® Index Builds Momentum for Cutting Edge Therapeutic Programs Targeting Multiple Cancers, Fibrotic Diseases, and Malaria ...
Providence, Rhode Island, Oct. 17, 2023 (GLOBE NEWSWIRE) -- Ocean Biomedical, Inc. (NASDAQ: OCEA), a biopharma company working to accelerate the development of compelling discoveries from top research ...
Providence, RI, May 16, 2023 (GLOBE NEWSWIRE) -- Ocean Biomedical, Inc. (NASDAQ: OCEA), a biopharma company working to accelerate the development and commercialization of scientifically compelling ...
Providence, RI, Jan. 29, 2025 (GLOBE NEWSWIRE) -- Ocean Biomedical (NASDAQ: OCEA) announced today that its Scientific Co-founder, Dr. Jonathan Kurtis, MD, PhD, and his research team have received ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results